Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza (MB).
Center of Biostatistics for Clinical Epidemiology, Dipartimento di Medicina e Chirurgia, Università degli Studi Milano-Bicocca, Monza (MB).
Haematologica. 2024 Feb 1;109(2):521-532. doi: 10.3324/haematol.2023.282805.
Diagnostic criteria for juvenile myelomonocytic leukemia (JMML) are currently well defined, however in some patients diagnosis still remains a challenge. Flow cytometry is a well established tool for diagnosis and follow-up of hematological malignancies, nevertheless it is not routinely used for JMML diagnosis. Herewith, we characterized the CD34+ hematopoietic precursor cells collected from 31 children with JMML using a combination of standardized EuroFlow antibody panels to assess the ability to discriminate JMML cells from normal/reactive bone marrow cell as controls (n=29) or from cells of children with other hematological diseases mimicking JMML (n=9). CD34+ precursors in JMML showed markedly reduced B-cell and erythroid-committed precursors compared to controls, whereas monocytic and CD7+ lymphoid precursors were significantly expanded. Moreover, aberrant immunophenotypes were consistently present in CD34+ precursors in JMML, while they were virtually absent in controls. Multivariate logistic regression analysis showed that combined assessment of the number of CD34+CD7+ lymphoid precursors and CD34+ aberrant precursors or erythroid precursors had a great potential in discriminating JMMLs versus controls. Importantly our scoring model allowed highly efficient discrimination of truly JMML versus patients with JMML-like diseases. In conclusion, we show for the first time that CD34+ precursors from JMML patients display a unique immunophenotypic profile which might contribute to a fast and accurate diagnosis of JMML worldwide by applying an easy to standardize single eight-color antibody combination.
目前,青少年髓单核细胞白血病 (JMML) 的诊断标准已经得到很好的定义,但在某些患者中,诊断仍然具有挑战性。流式细胞术是诊断和随访血液恶性肿瘤的成熟工具,但它并未常规用于 JMML 的诊断。在此,我们使用标准化的 EuroFlow 抗体组合来描述 31 名 JMML 患儿的 CD34+造血前体细胞,以评估其区分 JMML 细胞与正常/反应性骨髓细胞(n=29)或其他模仿 JMML 的血液系统疾病患儿细胞的能力(n=9)。与对照组相比,JMML 中的 CD34+前体细胞表现出明显减少的 B 细胞和红细胞定向前体细胞,而单核细胞和 CD7+淋巴样前体细胞则显著扩增。此外,JMML 中的 CD34+前体细胞中始终存在异常免疫表型,而在对照组中几乎不存在。多变量逻辑回归分析表明,联合评估 CD34+CD7+淋巴样前体细胞和 CD34+异常前体细胞或红细胞前体细胞的数量,在区分 JMML 与对照组方面具有很大的潜力。重要的是,我们的评分模型允许高度有效地区分真正的 JMML 与具有 JMML 样疾病的患者。总之,我们首次表明 JMML 患者的 CD34+前体细胞表现出独特的免疫表型特征,通过应用易于标准化的单一八色抗体组合,可能有助于在全球范围内快速、准确地诊断 JMML。